Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy

Next Previous
X
Search
Trial Profile

T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Decitabine (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Paclitaxel
  • Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 09 Aug 2022 Status changed from recruiting to active, no longer recruiting.
    • 05 Apr 2022 Planned number of patients changed from 32 to 50.
    • 05 Apr 2022 Planned End Date changed from 28 Feb 2023 to 28 Feb 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top